Zura Bio is developing dual-pathway therapies for severe autoimmune and inflammatory disorders, focusing on the efficacy and safety of its lead candidates, tibulizumab, crebankitug, and torudokimab. The company addresses the limitations of existing single-pathway treatments, aiming to improve patient outcomes and quality of life.
Funding
$112.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many autoimmune and inflammatory diseases are inadequately treated by existing therapies that target only a single disease pathway. Patients often require multiple medications to manage their conditions, leading to increased side effects and limited overall efficacy.
Solution
Zura Bio is developing a portfolio of dual-pathway therapies designed to address the limitations of single-target treatments for severe autoimmune and inflammatory disorders. Their investigational drugs, including tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), are being evaluated for their potential to improve patient outcomes by simultaneously modulating key pathways involved in disease pathogenesis. By targeting multiple mechanisms, Zura Bio aims to achieve greater efficacy, reduce the need for combination therapies, and enhance the safety profile of autoimmune and inflammatory disease treatments. The company is currently conducting Phase 2 clinical trials to assess the efficacy and safety of their lead candidate, tibulizumab, in systemic sclerosis and hidradenitis suppurativa.
Target Audience
The primary target audience includes patients suffering from severe autoimmune and inflammatory conditions, as well as physicians specializing in rheumatology, dermatology, and gastroenterology seeking more effective treatment options.
Features
- Tibulizumab (ZB-106): Investigational monoclonal antibody targeting a specific dual-pathway mechanism relevant in multiple autoimmune diseases; currently in Phase 2 clinical trials.
- Crebankitug (ZB-168): Novel therapeutic candidate engineered to modulate distinct, yet complementary, pathways implicated in inflammatory responses.
- Torudokimab (ZB-880): Preclinical asset with a unique mechanism of action designed to address unmet needs in specific autoimmune indications.
- Dual-pathway approach: Aims to provide more comprehensive disease control compared to single-target therapies.